---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-23-000048"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:48:01.147372+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics Q4 2022 net loss $98.7M; cash $1.34B; guides 2023 opex up 25-30%

## Summary
- Net loss $98.7M in Q4 2022 vs $75.3M in Q4 2021; full year net loss $326.0M vs $290.6M.
- Collaboration revenue $10.3M Q4, $108.5M FY2022; R&D expenses $92.1M Q4, $358.7M FY2022.
- Cash and marketable securities $1.34B as of Dec 31, 2022; raised $296.2M net in Oct 2022 public offering.
- 2023 guidance: cash operating expenses expected to increase 25-30% YoY, partially offset by up to $50M in partnership payments.
- Phase 2/3 COMPASS study for DNL310 (MPS II) enrolling; Phase 3 LIGHTHOUSE for BIIB122 (Parkinson's) initiated; Phase 2 HIMALAYA for DNL788 (ALS) recruitment completion expected end 2023.

## SEC filing metadata
- accession: 0001714899-23-000048
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/0001714899-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/dnli-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-23-000048
- JSON: https://secwatch.observer/filing/0001714899-23-000048.json
- Plain text: https://secwatch.observer/filing/0001714899-23-000048.txt

## Key facts
- Earnings Releases
  Denali Therapeutics Inc. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000048/0001714899-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.